FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2339-2340 November 25, 2004 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: As a result of the recent problems in the production of influenza vaccine, there is concern about whether the demand for vaccine will outstrip the supply for the upcoming influenza season.¹ An ample vaccine supply is an ever-present concern, given the potential for future influenza pandemics and avian influenza.² We recently evaluated 1/10th-dose influenza vaccine (Fluarix) as part of a larger phase 1b, randomized, controlled, double-blind vaccine study.³ Healthy volunteers (age range, 18 to 40 years) with negative results on screening tests of hemagglutination inhibition (HAI) for A/Beijing/262/95 and B/Harbin/7/94 were enrolled after they had given written . . . [Full Text of this Article]

This article has been cited by other articles:

• Falsey, A. R. (2008). Half-Dose Influenza Vaccine: Stretching the Supply or Wasting It?. Arch Intern Med 168: 2402-2403 [Full Text]